Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow ...
Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapy—European Blood and Marrow ...
... Melphalan or BEAM Conditioning Chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group ... Prospective Oral Mucositis Audit. Article.
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow ...
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow ...
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow ...
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow ...
... Melphalan or BEAM Conditioning Chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group ... Mucositis in Patients Receiving High-Dose ...
Nov 8, 2012 · Prospective oral mucositis audit : oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy : european blood ...
Jan 1, 2009 · ... in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT ... BLOOD, PALIFERMIN, INFECTION, DELIVERY, THERAPY ...